Research Square

Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice,
or referenced by the media as validated information.

Stk1 is required for BlaR1-mediated broad-spectrum β-lactam resistance in epidemic-causing strains of Staphylococcus aureus

Som Chatterjee

schatterjee@umaryland.edu

University of Maryland, Baltimore https://orcid.org/0000-0002-7138-4449

Raymond Poon

University of Maryland, Baltimore

Nidhi Satishkumar

University of Maryland, Baltimore

Wesley Mosimann

University of British Columbia

Vedangi Hayatnagarkar

University of Maryland, Baltimore

Vijay Hemmadi

University of Maryland, Baltimore

Skyler Kuhn

National Institutes of Health

Aditi Chatterjee

University of Maryland, Baltimore

Liam Worrall

University of British Columbia

Nathan Manes

National Institutes of Health

J. Andrew Alexander

University of British Columbia

Justin Lack

National Institute of Allergy and Infectious Diseases

Henry Chambers

University of California, San Francisco

Aleksandra Nita-Lazar

National Institutes of Health https://orcid.org/0000-0002-8523-605X

Natalie Strynadka

University of British Columbia

Article

Keywords:

Posted Date: January 12th, 2026

DOI: https://doi.org/10.21203/rs.3.rs-8331258/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

Additional Declarations: There is **NO** Competing Interest.

Version of Record: A version of this preprint was published at Nature Communications on September 16th, 2026. See the published version at https://doi.org/10.1038/s41467-026-77668-w.

Stk1 is required for BlaR1-mediated broad-spectrum β-lactam resistance in epidemic-causing strains of *Staphylococcus aureus*

Raymond Poon[1,2&], Nidhi Satishkumar[1,2&], Wesley A. Mosimann[3&], Vedangi Hayatnagarkar[1,2], Vijay Hemmadi[1,2], Skyler Kuhn[4], Aditi Chatterjee[1,2%], Liam Worrall[3], Nathan P. Manes[5], J. Andrew N. Alexander[3], Justin Lack[4], Henry F. Chambers[6], Aleksandra Nita-Lazar[5], Natalie C.J. Strynadka[3], Som S. Chatterjee[1,2#]

[1] Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, USA.

[2] Institute of Marine and Environmental Technology (IMET); Baltimore, MD, USA.

[3] Department of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.

[4] Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA.

[5] Functional Cellular Networks Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

[6] Division of Infectious Disease, Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA.

[&] Equal contributors

[%] Current address: University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.

[#] Corresponding author:

Som S. Chatterjee

Rita Rossi Colwell Center

701 Pratt Street

Baltimore, MD 21202

Tel: 410-234-8890

E-mail: schatterjee@umaryland.edu

Abstract

Sensory induction of *mecA* expression plays a pivotal role in mediating broad-spectrum β-lactam resistance (BBR) of MRSA. In contemporary MRSA isolates, sensory induction of BBR originates at the membrane-localized BlaR1, which, upon detection of β-lactam drugs, triggers a signal transduction cascade that promotes *mecA* induction. We hereby showed that phosphorylation of BlaR1, mediated through the serine-threonine kinase, Stk1, stabilizes its membrane spanning state and localization, allowing for proper drug sensing and subsequent signal transduction events to occur, culminating in *mecA*-mediated BBR. Our results demonstrated that targeting Stk1 could potentiate synthetic lethality to β-lactams in the majority of naturally isolated strains of MRSA. We also presented the structural and kinetic basis for a Stk1-inhibitor complex that could enable rational design of Stk1 directed anti-MRSA therapeutics in the future. Our results reveal a unique and hitherto unknown role of the STK signaling pathway in bacterial protein stabilization in the cytosolic membrane.

Introduction

Staphylococcus aureus is a frequent colonizer of the human population and an opportunistic pathogen[1]. *S. aureus* is also infamous for its ability to resist treatment by important antibiotics such as β-lactams, vancomycin, and daptomycin[2].

Eukaryotic-like (Hanks-type) serine-threonine kinase (STK) phospho-regulation pathways are universally present in bacteria and mediates important cellular processes[3]. In *S. aureus* and other Firmicutes, the STK kinase, Stk1 (also known as PknB or PrkC), belongs to the Penicillin-binding protein And Serine/Threonine kinase-Associated (PASTA) kinase class. Stk1 functions in concert with Stp1, its cognate phosphatase, to mediate phosphorylation and dephosphorylation of serine, threonine, or tyrosine residues of target proteins. STK signaling in *S. aureus* regulates numerous cellular pathways, including cell wall biosynthesis[4,5], bacterial quiescence[6], virulence[7], and β-lactam resistance[8].

β-lactam antibiotics are known for their excellent efficacy and safety, making them the most commonly prescribed class of drugs to treat infections[9]. In *S. aureus*, resistance to β-lactams can be detected in the form of narrow- or broad-spectrum resistance[2]. Resistance to early-generation β-lactams such as penicillin, driven by the β-lactamase PC1 and encoded by plasmid-associated *blaZ*[10,11], is termed narrow-spectrum resistance. Resistance to next-generation β-lactams, such as methicillin and its newer derivatives, including advanced cephalosporins, is categorized as broad-spectrum resistance or methicillin resistance. Such resistance is usually displayed by methicillin-resistant *S. aureus* (MRSA) isolates and is facilitated by a low-affinity penicillin-binding protein, PBP2a, encoded by *mecA* (or *mecC*) embedded within a chromosomal cassette (SCC*mec*)[12]. Similar but separate inducible pathways are known to control both resistance mechanisms[13]. When expression of *blaZ* or *mecA* is unwarranted, the repressors, BlaI or MecI, respectively, suppress their transcription. BlaR1 or MecR1 are membrane-embedded sensor-inducer proteins that detect the presence of β-lactam drugs in the bacterial surroundings, which culminates in a signal transduction process that promotes degradation of BlaI or MecI to de-

repress *blaZ* or *mecA* expression, respectively. The above pathways allow for inducible expression of *blaZ* or *mecA*, ensuring timely expression of the β-lactam resistance mediators when needed.

Previous studies have further indicated that the BlaI and MecI repressors, in addition to regulating their corresponding target genes (i.e., *blaZ* and *mecA*), can also cross-regulate *mecA* and *blaZ* expression owing to their high sequence homology and similar DNA recognition sequence[14,15]. This ability of cross-regulation between the two systems is exemplified in strains containing SCC*mec* clusters that are deficient of functionally active *mecR1-mecI* regulatory genes, one example being *S. aureus* strains that contain the type IV SCC*mec* cluster[16]. A prominent community- and healthcare-associated epidemic causing MRSA strain, USA300, contains the type IV SCC*mec* cluster that is dependent on the *bla* system for *mecA* regulation[17] **(Fig. 1a)**. Notably, the majority of the identified SCC*mec* cluster types (9 of the total identified 15 types, to date) have functionally inactive *mecR1-mecI* regulatory genes[18-20]. Thus, in the vast majority of MRSA strains, the plasmid encoded BlaR1-BlaI regulatory system could confer both narrow- and broad-spectrum β-lactam resistance, making it the sole regulatory pathway associated with both modes of β-lactam resistance.

While much of the mechanistic understanding of the BlaR1-BlaI signal transduction pathway remains to be elucidated, previous studies have indicated that BlaR1 is phosphorylated by Stk1, and inhibition of Stk1 leads to decreased BlaZ activity as well as narrow-spectrum β-lactam resistance[21]. The mechanism by which inhibition of Stk1 leads to decreased BlaZ activity is however unknown. Additionally, the role of Stp1, the cognate phosphatase of the STK pathway in controlling β-lactam resistance, remains undetermined.

In this study, we reveal that Stk1 functionality is essential for the successful induction of *blaZ* and *mecA* via the BlaR1-BlaI signal transduction pathway, by facilitating stabilization of the membrane inserted species of the polytopic BlaR1. Inhibition of Stk1 functionality, either by deletion of the *stk1* gene or in the presence of its inhibitor GW779439X (GWX), resulted in decreased levels of

membrane-localized BlaR1, subsequently leading to attenuated degradation of BlaI and compromised induction of *mecA* expression. Decreased induction of *mecA* in turn led to decreased protein levels of PBP2a and prompted synthetic lethality in bacteria to broad-spectrum β-lactam drugs. Furthermore, our results suggested that stabilization of membrane inserted BlaR1 is not only coupled with its Stk1-mediated phosphorylation status but occurs in a β-lactam-independent manner. Our results highlight the hitherto unknown role of a posttranscriptional modification of BlaR1 in facilitating proper localization into the bacterial membrane. Through performing high-throughput bioinformatics analysis and providing the structural basis of Stk1-GWX inhibition, we uncover the mechanistic basis of Stk1's involvement in broad-spectrum β-lactam resistance. Additionally, through performing *C. elegans* model of infection we present Stk1 as a potential target of therapeutic development against MRSA.

Materials and Methods

Bacterial strains and plasmids

S. aureus strains were cultured in tryptic soy broth (TSB) (BD Biosciences) at 37°C with shaking at 180 rpm. *E. coli* cultures were grown in Luria Bertani (LB) broth at 37°C with shaking at 180 rpm unless mentioned otherwise. *S. aureus* carrying the constitutively expressing (*pTX*$_{\Delta}$) or a xylose-inducible (*pTX15*) vector were cultured in media supplemented with 12.5 µg/mL tetracycline[8,22]. Strains with the *pTX15* vector were grown in TSB without dextrose. All the strains and plasmids used in this study are listed in **Tables S1 and S2,** respectively.

Mutant construction

Isogenic *S. aureus* Δ*stk1* and Δ*stp1* mutants were created using the *pJB38* vector as previously described[8,22]. Briefly, a splice-overlap PCR product with at least 1 kb up- and downstream of the target gene was cloned into *pJB38.* The construct was transformed into the *E. coli* strain DH5α, electroporated into *S. aureus* RN4220, and then finally phage transduced into recipient *S. aureus* strains. Allelic replacement was performed as previously described[23]. Primers used in this study are listed in **Table S3**.

Growth curve assays

Growth assays were performed using the Bioscreen C Pro automated growth curve machine (Growth Curves USA), starting from an initial OD_{600} of 0.1. When needed, antibiotics nafcillin or oxacillin (Sigma), or the Stk1 inhibitor GW779439X (GWX) (MedchemExpress) were added at the start of the experiments at the required concentrations. CFU measurements were performed by sampling the Bioscreen plate at 12 h, serial diluting the cultures with phosphate-buffered saline (PBS), plating on TSA only or TSA plates containing tetracycline, and incubating overnight at 37°C. Each experiment was performed twice with 3 technical replicates to ensure reproducibility. Statistical analysis was performed using an unpaired Student's t-test with GraphPad Prism.

Transmission Electron Microscopic analysis

Electron microscopy was carried out at the core imaging facility at the University of Maryland, Baltimore. *S. aureus* strains were cultured in 50 mL of TSB in flasks from a starting OD_{600} of 0.1 under the conditions specified above. After 2 h of growth, either 0 or 8 µg/mL of nafcillin was added to the flasks, which were grown for an additional 4 h. 1 mL of bacterial culture was harvested, pelleted, washed with PBS, and fixed with 2.5% glutaraldehyde in 0.1 M PIPES buffer pH 7.4. The cells were washed again, pelleted, enrobed in 2.5% low-melting-point agarose, and post-fixed with 1% osmium tetroxide, 0.25% potassium ferrocyanide in 0.1 M PIPES buffer pH 7.4 for 1 h at room temperature. Agarose blocks containing cells were washed and *en bloc* stained with 1% uranyl acetate in water for 60 min, then washed and dehydrated using increasing concentrations of acetone, including 30%, 50%, 70%, 90%, and 100% for 10 min at each step. Specimens were infiltrated in increasing concentrations of Araldite-Embed 812 resin (EMS, PA) following the manufacturer's instructions and embedded in pure resin at 60°C for 24 to 48 h. Ultrathin sections of ~70 nm thickness were cut on a Leica UC6 ultramicrotome (Leica Microsystems, Inc., Bannockburn, IL), collected onto copper grids, and examined in a Tecnai T12 transmission electron microscope (Thermo Scientific) operated at 80 kV. Digital images were acquired by using an AMT bottom-mount CCD camera and AMT600 software.

Custom antibody creation

Custom polyclonal rabbit antibodies were generated by Thermo Fisher using their standard 70-day rabbit immunization protocol. Briefly, New Zealand White rabbits were immunized with synthetically generated amino acid peptides (BlaR1 Cytosolic Loop: KNEFKTYAESIMDSVLKTP; BlaI: ELNNKEIEELRDILNDISKK; Stk1: REKEETLKRFEREVHNS; Stp1: RLLVKEGTIEDHGDQLMQL; SrtA: DDYNEKTGVWEKRKIFVATEVK) over the course of 70 days. Serum was collected on days 35 and 58 and analyzed via ELISA test to verify antibody titers. A final terminal bleed was performed on day 70, and the collected serum was used for experiments.

Immunoblotting

S. aureus strains were cultured in 50 mL of TSB in flasks from a starting OD_{600} of 0.1 under conditions specified above. Following appropriate treatment with antibiotics and/or the GWX inhibitor, cells were harvested, washed with PBS, then resuspended in Immunoblotting Lysis Buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2mM EDTA, 1 mM Sodium Pyrophosphate, 1X cOmplete Mini™ protease inhibitor cocktail (Roche)). Cells were lysed mechanically using a FastPrep-24 Classic bead-beating machine (MP Biomedicals) with 4 cycles of speed 6.5 m/s for 45 s to obtain whole cell lysates. Membrane fractions from cell lysates were isolated via ultracentrifugation using a Sorvall WX Ultra 80 centrifuge (Thermo Fisher Scientific) at 66,000 Xg for 1 h at 4°C. The supernatant (cytosol fraction) was carefully removed and saved while the pellet was resuspended with Immunoblotting Lysis Buffer. Protein quantification was carried out using a Pierce BCA protein assay kit (Thermo Fisher), following which 20 µg of protein samples were separated on SDS-PAGE gel using the appropriate polyacrylamide gel concentration (BlaI: 15%; PBP2a, BlaR1, Stk1, Stp1: 10%). SDS-PAGE gels were transferred onto a low-fluorescence polyvinylidene difluoride (PVDF) membrane (Sigma Millipore) using a semi-dry transfer buffer (48 mM Tris base, 39 mM glycine, 20% methanol) and a semi-dry transfer unit (Bio-Rad) set at 20 V, 350 mA for 90 min. The blots were first blocked using Intercept (TBS) Blocking Solution (Li-Cor) for 1 h at room temperature. Primary antibody incubation was carried out overnight at 4°C by diluting the antibody in Intercept (TBS) containing 0.2% Tween-20 at appropriate concentrations (Rabbit anti-BlaI: 1:500; Rabbit anti-BlaR1: 1:500; Rabbit anti-PBP2a [Product #130-10178, RayBiotech]: 1:500; Rabbit anti-Stk1: 1:1000; Rabbit anti-Stp1: 1:2000; Rabbit anti-SrtA: 1:1000; Mouse anti-Spa [Product#P2921-.2ML, Sigma]: 1:1000; Mouse anti-P-Tyrosine [Product #96215, Cell Signaling]: 1:1000; Mouse anti-His-Tag [Product # MA1-21315, Invitrogen]: 1:1000). For duplex staining, the blot was washed with TBST and probed for an additional 2 h at 4°C with a second primary antibody. Next, after washing the blots with TBST, blots were incubated for at least 1 h at room temperature with a secondary antibody at appropriate concentrations (anti-Rabbit 700nm: 1:15,000 or anti-Mouse 800nm: 1:10,000) in Intercept (TBS) containing 0.2%

Tween-20 and 0.01% SDS. Loading controls were included by probing for Sortase A by cutting the blot in half and incubating the section with anti-SrtA primary antibody, and/or including a Coomassie-stained gel for each immunoblot. For Coomassie staining, gels were incubated in Coomassie stain (0.25% Coomassie Brilliant Blue, 40% methanol, 10% acetic acid in water) for 2 h and de-stained using De-stain solution (50% methanol, 10% acetic acid in water). Imaging was performed using the Azure 600 imaging machine (Azure Biosystems). Blots showing quantitative differences were performed thrice, and densitometry analysis was performed using ImageJ. Statistical analysis was carried out using an unpaired Student's t-test on GraphPad Prism. Blots showing qualitative differences were performed twice.

Densitometry analysis was performed using ImageJ. Briefly, the Western blot image was imported into ImageJ and each lane was highlighted using the rectangle tool. A pixel darkness histogram was generated from the aforementioned rectangles. The histograms were further gated on the bottom and sides of each band peak. The bottom gate follows the slope of the background signal of the PVDF membrane. The side gates are vertical gates at the point of the band peak where the tangent to the curve is at a 45-degree angle (to allow for standardization of the area under the peak when bands are close together). The area under the peak was calculated after gating. Statistical analysis was carried out using an unpaired Student's t-test on GraphPad Prism.

Bacterial total RNA isolation and qRT-PCR analysis

S. aureus strains were cultured in 50 mL of TSB in flasks from a starting OD_{600} of 0.1 under the conditions specified above. Following appropriate treatment with antibiotics and/or the GWX inhibitor, approximately 5×10^9 bacterial cells were harvested and washed with RNase-free water. Cells were resuspended in RLT Buffer from the RNeasy Mini Kit (Qiagen) and supplemented with 0.1% 2-mercaptoethanol. Cells were mechanically lysed using the FastPrep-24 Classic bead beating machine (MP Biomedicals) with 2 cycles of speed 6.0 m/s for 45 s. After lysis, total RNA was isolated using the RNeasy Mini Kit (Qiagen), and cDNA was synthesized as described

previously[24]. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed in a 7500 Real-Time PCR System (Applied Biosystems) using SYBR Green PCR Master Mix (Thermo Fisher) with *gyrB* as a housekeeping control. Primers used in qRT-PCR are listed in **Table S4**. Each experiment was performed twice to ensure reproducibility. Data analysis was performed using Microsoft Excel and statistical analysis was performed using an unpaired Student's t-test on GraphPad Prism.

Bioinformatics analysis

To analyze the distribution of key antibiotic resistance genes in *S. aureus* strains, all publicly available *S. aureus* genome assemblies deposited into the National Center for Biotechnology Information (NCBI) database[25] were downloaded and combined to build a custom BLAST nucleotide database using the makeblastdb application from the BLAST+ suite (version 2.15.0+)[26]. The full-length nucleotide sequences of the target genes of interest (*stp1*: Genbank: CP000730.1, locus tag: USA300HOU_1156; *stk1*: Genbank: CP000730.1, locus tag: USA300HOU_1157; *mecA*: Genbank: CP000730.1, locus tag: USA300HOU_0031; *mecI*: Genbank: BA000018.3, locus tag: SA_RS00345; *blaZ*: Genbank: CP000730.1, locus tag: USA300HOU_pUSA300HOUMR0011; and *blaI*: Genbank: CP000730.1, locus tag: USA300HOU_pUSA300HOUMR0013) were queried against the custom *S. aureus* BLAST database using blastn[26] with the `-max_target_seqs` option. In the case of a genome accession having multiple hits per query, only the single top-scoring hit was chosen, prioritizing alignments with the greatest percent identity and alignment length. Hits were filtered using the following criteria to minimize false positives: (i) an alignment length fraction ≥ 0.95 (i.e., ≥ 95% of the gene length aligned) and (ii) percent nucleotide identity ≥ 95%. The alignment length fraction was calculated as the aligned region divided by the full length of the query gene. A total of 127894 *S. aureus* genome accessions were used in this analysis.

The protein multiple sequence alignment of the kinase domain of *S. aureus* strain Mu50 Stk1 (Genbank: WP_000579563.1; identical to Stk1 from USA300) against the kinase domains of various Hanks-type kinases was performed using Clustal Omega. The aligned sequences include *B. subtilis* strain 168 (PrkC, Genbank: NP_389459.1), *M. tuberculosis* strain H37Rv (PknB, Genbank: NP_214528.1), *H. sapiens* (ABL1, Uniprot: P00519), and *E. faecalis* (IreK, GenBank: WP_002387383).

Protein expression and purification

The kinase domain (residues 1-291) of *stk1* (Stk1 KD) from *S. aureus* strain Mu50 (ATCC 700699) was cloned into the expression vector *pET28b* (+) using primers listed in **Table S3** and transformed into *E. coli* BL21 (DE3) as described previously[27]. The vector includes an N-terminal 10X His-tag followed by a thrombin cleavage site. Overnight cultures of BL21 (DE3) were sub-cultured at a starting dilution of 1:100 and grown in Terrific Broth (TB) media supplemented with 50 µg/mL kanamycin under conditions mentioned above until they reached an OD_{600} of 0.6. 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) was added to the media to induce protein expression and the culture was incubated for 16 h at 23°C and 180 rpm. Cells were then harvested and pelleted at 6,200 x g for 15 min, following which the pellet was resuspended in 4 mL/gm in Lysis Buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole, 0.1X cOmplete Mini Protease Inhibitor Cocktail (Roche)). Cell lysis was performed by doing two passes through a CF1 Cell Disruptor (Constant Systems Ltd.) at a pressure of 30 kPSI. The insoluble fraction was pelleted via centrifugation at 40,000 g for 45 min at 4°C. The supernatant was filtered through a 45 µm filter and loaded onto a gravity Ni-NTA column (Thermo Scientific HisPur Ni-NTA resin) pre-equilibrated with Buffer A (20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole). The resin was washed with 10X column volume (CV) of Buffer A, followed by 10X CV of Buffer B (20 mM HEPES pH 7.5, 150 mM NaCl, 50 mM imidazole). The protein was then eluted with 10X CV of Elution Buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 300 mM imidazole). Eluted fractions were

pooled and dialyzed into Buffer C (20 mM HEPES pH 7.5, 150 mM NaCl) using a 3.5 kDa MWCO membrane (Repligen). The dialyzed proteins were incubated with a 1:1000 molar ratio of bovine α-thrombin (HTI) overnight at 4°C. Subsequently, the 10X His-tag cleaved proteins were passed over the Ni-NTA resin once again to remove the His10-tag and any uncleaved protein. The remaining protein was injected into a Superdex 200 10/300 GL size exclusion column (GE Life Sciences) equilibrated with Buffer C. Fractions containing the thrombin-cleaved Stk1 KD were concentrated using a 10 kDa MWCO Amicon Ultra centrifugal filter (Millipore Sigma).

Crystallization and X-ray crystallographic analysis of STK1 with GWX inhibitor

A solution of 9 mg/mL of purified Stk1 KD, 5 mM $MgCl_2$, 2% (w/v) benzamidine hydrochloride, 1 mM dithiothreitol, 20 mM HEPES pH 7.5, 150 mM NaCl, and 2 mM of Stk1 inhibitor GWX was drop-wise added onto 24-well Cryschem plates (Hampton Research) at 22°C using the sitting drop vapor diffusion method. The drop that yielded the best diffracting crystals contained 1 µL of protein solution mixed with 1 µL of reservoir solution (80 mM 2-(N-morpholino)-ethanesulfonic acid pH 6.0, 1.2 M sodium citrate pH 7.0, 2% (w/v) benzamidine hydrochloride, and 30 mM $MgCl_2$), optimized relative to an earlier report[4]. Crystals were grown at 4°C and began to appear after 1-2 days, achieving a maximal size of up to 400 µm in approximately one week. To improve the size and quality of the crystals, a pinprick hole was applied to the sitting drop well to allow for controlled evaporation. The crystals belong to space group $P4_32_12$ with a single Stk1 KD chain in the asymmetric unit. Crystals were looped and flash frozen in liquid nitrogen using the high sodium citrate concentration of the mother liquor as a cryoprotectant prior to data collection.

X-ray diffraction experiments were performed at the Canadian Light Source (CLS) at the University of Saskatchewan in Saskatoon, Saskatchewan, Canada. Data was collected at 100 K on the CMCF-BM (08B1) beam line with a Pilatus3 S 6M X-ray detector using MxDC data collection software. Diffraction data were processed using XDS[28], and data reduction was performed with Aimless[29] through the CCP4 software[30]. Data were corrected for anisotropic

diffraction through elliptic truncation using the STARANISO server[31]. Phasing was carried out with molecular replacement using PDB 4EQM, chain A as the search model for Phaser-MR[32] as part of the Phenix[33] software package. The initial model was iterated upon through alternating steps of model building in Coot[34] and refinement in Phenix. Model validation was carried out using MolProbity[35]. Final model and refinement statistics are provided in **Table S5**. Coordinates have been deposited to the Protein Data Bank with PDB code 9YMT. Figures were created using PyMOL[36].

Stk1 KD activity assay and inhibition by GWX

Kinase activity assays were performed using the ADP-Quest assay kit (DiscoverX)[37]. The assay was programmed to run in a BioTek Synergy H1 microplate reader for 10 min at 25°C with excitation and emission wavelengths of 530 nm and 590 nm, respectively. Black polypropylene 96-well microplates (Greiner Bio-One) were used for assays with a final volume of 100 µL. 2-fold serial dilutions of GWX were incubated with STK1 for 5 min to allow for binding before combining with the remaining reactants. Measurements were performed with final concentrations of 100 nM STK1, 100 µM ATP, 1X Buffer A (20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole), 1X Buffer B (20 mM HEPES pH 7.5, 150 mM NaCl, 50 mM imidazole), 2% DMSO, and 2000 nM-4 nM GWX.

Data analysis was performed using Microsoft Excel and a kinetics analysis was performed using non-linear regression, variable Hill slope in GraphPad Prism. Initial reaction rates were determined from the linear part of the progress curves. Inhibition of Stk1 at each inhibitor concentration was determined by comparing the rates of each compound against the "maximum rate" of uninhibited Stk1 (with 2% DMSO) after subtracting the background.

$$\%\text{Inhibition} = 100 \times \left(1 - \left[\frac{(\text{Rate} - \text{Background Rate})}{(\text{Maximum Rate} - \text{Background Rate})}\right]\right)$$

IC_{50} values and errors were derived from the non-linear regression analysis of these % inhibition curves using GraphPad Prism.

Isothermal Titration Calorimetry binding data of Stk1 KD and GWX inhibitor

Isothermal titration calorimetry (ITC) measurements were performed using a MicroCal PEAQ-ITC instrument (Malvern) at 25°C in high-feedback mode with a stirring speed of 750 rpm for sixteen 2 µL injections. GWX powder was solubilized to a concentration of 200-400 µM in Buffer D (20 mM HEPES pH 7.5, 150 mM NaCl, 2% DMSO) and then titrated into 13-20 µM purified Stk1 KD in a 200 µL volume to measure the heat of interaction. A control titration of GWX into Buffer D was integrated, and the resulting heat of dilution of the titrant was subtracted from the integrated heats of interaction to correct for it. The obtained data were fitted with a one-binding-site model to determine K_d, ΔH, ΔS, and the number of binding sites (n) using MicroCal PEAQ-ITC Analysis Software v1.41 (Malvern). Experiments and controls were performed in triplicate, and error analysis was performed using the Analysis Software package.

***Caenorhabditis elegans* killing assay**

Infection of *C. elegans* DH26 was performed as described previously[24]. Briefly, after age synchronization, 15 L4 young adult worms were incubated with 1.5×10^5 *S. aureus* in each well of a 96-well flat plate. Bacteria were suspended in 100 µL Liquid Assay media (80% M9 buffer, 20% TSB, 10 µg/mL cholesterol, and 7.5 µg/mL nalidixic acid). Nafcillin and/ or GWX were added at the indicated concentrations. The worms were incubated at 26°C, and the survival rate was recorded at 72 h after the addition of bacteria.

Results

***mecA* expression is mediated by the BlaR1-BlaI pathway in a majority of MRSA isolates**

The MecI-MecR1 regulatory pathway is recognized to be impaired in a majority of known SCC*mec* types[12]. To better determine the predominance of MRSA where *mecA* was regulated via the

BlaR1-BlaI pathway, we assessed all available *S. aureus* genomic entries on NCBI, including those for which only shotgun sequences were available. Of the 127,894 *S. aureus* entries found, 61.34% represented MRSA, as they were positive for *mecA*. A majority (85.19%) of these MRSA entries were positive for *blaZ* and *blaI*, which served as a surrogate to determine the presence of the Bla regulatory pathway **(Fig. 1b)**. Interestingly, a significant proportion of the MRSA entries (75.90%) did not possess the *mecI* gene. Moreover, most of the entries devoid of *mecI* were positive for the *blaZ* and *blaI* genes (90.27%), signifying that the MecI-MecR1 pathway was impaired in a significant proportion of MRSA, and that *mecA* expression was under the control of the BlaR1-BlaI regulon in these entries **(Fig. 1b)**. The above analysis demonstrated that BlaR1-BlaI-mediated *mecA* expression played a vital role in mediating broad-spectrum β-lactam resistance among a majority of the natural MRSA isolates sequenced to date. A prior study identified a key step in the activation of β-lactam resistance was the phosphorylation of the sensor-inducer protein BlaR1, following β-lactam detection[21,38]. This phosphorylation of BlaR1 has been attributed to Stk1, the kinase counterpart of the eSTK1 signaling pathway. Notably, we found *stk1* and *stp1*, the two components of the eSTK1 pathway to be conserved in 99.71% of our 127894 analyzed *S. aureus* entries **(Fig. 1b)**. In addition to *S. aureus*, the *stk1* and *stp1* genes are also conserved in several staphylococcal species[39] as a bicistronic operon[7,40]. These analyses together suggest that the eSTK1 signaling pathway is highly conserved and plays an important role in β-lactam resistance.

Deletion of *stk1* induces synthetic lethality to broad-spectrum β-lactam drugs

In order to determine the role of the *stk1-stp1* operon on β-lactam resistance in MRSA, we deleted *stk1* or *stp1* from SF8300, a clinically isolated USA300 strain[2] that contains an impaired MecR1-MecI regulatory pathway (type IV SCC*mec*) and has *mecA* controlled by the BlaR1-BlaI regulatory pathway. Following successful phenotypic validation of the deletion mutants **(Figs. 1c, d and Figs. S1a, b)**, we performed growth assays for Wt (wild type), Δ*stk1*, and Δ*stp1* in the absence

or presence of nafcillin or oxacillin, two representative broad-spectrum, clinically relevant β-lactam drugs[41-43]. Growth assay without β-lactams (untreated) resulted in similar growth curves and bacterial CFUs for the three isogenic strains, suggesting that deletion of either of the genes did not cause a growth defect when evaluated in rich culture media **(Figs. 1e)**. On the contrary, β-lactam treatment resulted in significantly attenuated bacterial growth and CFU formation for Δ*stk1* when compared to Wt and Δ*stp1*, indicating that the loss of Stk1 led to β-lactam susceptibility **(Fig. 1e)**. To determine the reproducibility of these results we deleted Δ*stk1* and Δ*stp1* in MW2, a clinically isolated, β-lactamase positive, USA400 strain[2] with type IV SCC*mec*, and found a similar growth attenuation in Δ*stk1* treated with β-lactams when compared to Wt and Δ*stp1* **(Fig. S1c)**. These findings suggested that the deletion of *stk1* resulted in synthetic lethality to broad-spectrum β-lactams. We evaluated the basis of β-lactam susceptibility in Δ*stk1* by performing electron microscopy and detected substantial cell lysis in Δ*stk1* samples treated with nafcillin, compared to Wt and Δ*stp1* **(Fig. 1f, Fig S1d)**. When untreated, no significant morphological differences were detected amongst the isogenic strains, demonstrating that the altered growth phenotype of Δ*stk1* was due to cell lysis caused by β-lactam exposure, and not due to factors such as growth arrest or small colony formation. Survival patterns and morphological characteristics of Δ*stp1* in the presence of β-lactams were similar to or greater than those seen in Wt for both SF8300 and MW2, demonstrating that loss of *stp1* was favorable for β-lactam resistance **(Figs. 1e-f, Fig. S1c-d)**.

To associate Stk1 function with the susceptible phenotypes of Δ*stk1*, we complemented the mutant with either an empty vector (E), wild-type *stk1* (Wt), or a mutant *stk1* (K39G), using a constitutively expressing vector, pTX_{Δ} **(Figs. 2a-b, S1e-f)**. The K39G mutation renders Stk1 incapable of auto-phosphorylation, as well as target protein phosphorylation, making it enzymatically inactive[40]. When untreated, we detected comparable growth and CFUs for all complemented mutants, suggesting that neither the loss nor the constitutive expression of Stk1 had adverse effects on bacterial growth **(Fig. 2c)**. However, in presence of β-lactams, the Δ*stk1*

[*stk1* (Wt)] strain showed increased survival as seen by enhanced growth and CFU formation compared to Δ*stk1* [E] and Δ*stk1* [*stk1* (K39G)]. These results indicated that the synthetic lethality of Δ*stk1* was indeed due to the loss of Stk1 function and that Stk1 function was necessary for the production of β-lactam resistance. To associate the Stk1 dose with the magnitude of β-lactam resistance, we performed Δ*stk1* complementation using a xylose-inducible vector, p*TX15.* Growth curves for the resultant complemented strains were similar when untreated, with or without xylose induction **(Fig. 2d)**. Upon nafcillin exposure, Δ*stk1* [*stk1* (Wt)] remained susceptible at 0% xylose, but gained resistance as seen by enhanced growth when induced with increasing concentrations of xylose. At the highest xylose concentration of 0.2%, the growth curve of Δ*stk1* [*stk1* (Wt)] was comparable to that displayed by Wt [E], indicating complete loss of susceptibility. Δ*stk1* [*stk1* (K39G)] remained susceptible even at 0.2% xylose, substantiating that Stk1 function played a crucial role in mediating broad-spectrum β-lactam resistance **(Fig. 2d)**.

We verified the phenotype identified in Δ*stp1* **(Figs. 1e-f)** by complementing it with an empty vector (E), wild-type *stp1* (Wt), or a functionally inactive mutant of *stp1* (G40A)[44] using the constitutively expressing vector, pTX_{Δ} **(Figs. 2a-b, S1e-f)**. All strains had similar growth patterns when untreated **(Fig. 2e)**. In presence of β-lactams, Δ*stp1* [E] and Δ*stp1* [*stp1* (G40A)] remained resistant to nafcillin and oxacillin, while the presence of a functional Stp1 in Δ*stp1* [*stp1* (Wt)] led to significant decrease in growth, indicating β-lactam susceptibility. These findings confirmed that the enhanced β-lactam survival seen in Δ*stp1* **(Figs. 1e-f)** was due to loss of Stp1 function, and indicated that Stk1 and Stp1 affected β-lactam resistance in a contrasting manner.

Stk1 is required for efficient induction of *mecA* upon broad-spectrum β-lactam exposure

Since efficient induction of *mecA* expression is required for the manifestation of broad-spectrum β-lactam resistance, we next investigated whether Stk1 played any role in *mecA* expression by quantifying the increase in *mecA* transcripts and PBP2a expression in response to β-lactam exposure **(Figs. 3a-e)**. qRT-PCR analysis revealed that exposure to nafcillin **(Fig. 3a)** or oxacillin

(Fig. 3b) led to a significantly attenuated induction of *mecA* transcription in Δ*stk1* when compared to Wt and Δ*stp1* **(Figs. 3a-b)**. To validate these at the protein level, we performed immunoblotting to determine the expression of PBP2a among the isogenic strains **(Figs. 3c-e)**. When untreated, PBP2a expression was minimal but comparable among all three strains **(Figs. 3c, S2a)**. Nafcillin **(Fig. 3d, S2a)** or oxacillin **(Fig. 3e, S2a)** exposure led PBP2a induction in all three strains, but Δ*stk1* induced PBP2a significantly less when compared to Wt and Δ*stp1*. Thus, findings of immunoblotting assays were consistent with those of qRT-PCR, demonstrating that during β-lactam exposure, Δ*stk1* had a dampened *mecA* induction that resulted in inadequate PBP2a expression and β-lactam susceptibility.

Chemical inhibition of Stk1 function in wild-type bacteria produces sensitivity to broad-spectrum β-lactams by attenuating *mecA* induction

Since the above findings suggested that loss of Stk1 function was favorable for sensitization of MRSA to broad-spectrum β-lactams **(Figs. 1e, 2c)**, we used GW779439X (GWX), an established kinase inhibitor, to inhibit Stk1 function in Wt[45]. We validated the *in vitro* activity of GWX to inhibit the *S. aureus* kinase domain ($Stk1^{1-291}$) through the commercially available ADP-QuestTM assay kit, which monitors kinase-induced ADP production via fluorescence[46]. The ability of the GWX inhibitor to abrogate kinase activity was tested using this assay, which produced an *in vitro* IC50 value of 188.5 nM[46] **(Fig. 3f)**. Next, we used isothermal titration calorimetry (ITC) to determine the thermodynamic parameters associated with the binding of GWX to $Stk1^{1-291}$ with a calculated K_d of 21.1nM ± 11.1nM (**Fig. S2b)** highlighting the potent nature of GWX. To investigate the molecular basis of Stk1 inhibition by GWX in further detail, we co-crystallized the protein-ligand complex and determined its structure through X-ray diffraction methods to a 2.1 Å resolution **(Table S5)**. $Stk1^{1-291}$ adopts a Hanks-type kinase fold, a highly conserved fold common to many prokaryotic and eukaryotic kinases[39,47]. This fold has a characteristic bi-lobal feature with an N-terminal lobe (N-lobe) comprised of a 5-stranded β-sheet connected primarily through β-hairpins

and a regulatory α-helix known as the C-helix, while the C-terminal lobe (C-lobe) is comprised of primarily helices and loops **(Figs. 3g-h, Figs S2c-d)**. The Stk1-GWX inhibitor complex structure superposes closely with that of the previously solved Stk1 structure bound to the non-cleavable substrate analog AMP-PNP (PDB ID: 4EQM[27]). Using PyMol's align function, model 4EQM was compared to our structure across all residues with a final RMSD of 0.608 Å after 5 cycles, indicating little conformational difference in the kinase domain upon binding of GWX. The N- and C-lobes of the kinase domain create an extensive active site cleft at their interface which accommodate the ATP and protein substrates upon which it acts. In our inhibited structure, this cleft is occupied instead by the substrate analog GWX ligand. In the crystallographic structure determined here, residues 161-170 and 284-291 remain unmodelled due to disorder in the corresponding regions of the electron density maps, and likely as a result of the high flexibility of the so-termed activation loop and the C-terminus, respectively. The activation loop is one of the regulatory elements of the kinase active site, participating in protein-protein interactions, regulating substrate specificity and containing conserved serine/threonine residues used in autophosphorylation/transphosphorylation. These regions were also lacking clear electron density and were presumed dynamic in the prior AMP-PNP structures, 4EQM. In our structure of the kinase domain, Asp 151 of the DFG motif is pushed away from the active site cleft into the "DFG-out," conformation where it can no longer participate in the co-ordination of magnesium ions as part of its role in catalysis[48,49]. Instead, the preceding Phe150 lies in the adenine pocket and forms a pi-stacking interaction with the pyrazolopyridine moiety of the GWX ligand. The αC-helix of $Stk1^{1-291}$ also adopts the inactive conformer and is positioned such that the conserved Glu 58 in the C-Helix is blocked by the activation loop, preventing it from making a salt-bridge with Lys 39, a key electrostatic determinant of kinase activation that we have mutated for a phosphorylation-deficient strain in other aspects of this study [50,51] **(Figs. 2c and 3g-h)**. (Refer to supplementary text for more results).

After determining the molecular basis of GWX-mediated Stk1 inhibition, the only conserved hanks-type kinase in *S aureus*, we examined the phenotypic effect of using the inhibitor in combination with β-lactams in Wt and Δ*stk1.* We first carried out a growth assay with GWX alone and found that the inhibitor did not cause any phenotypic alterations, as both Wt and Δ*stk1* had similar growth patterns without and with GWX **(Fig. 3i)**. We then treated Wt with nafcillin combined with a range of GWX concentrations (0-0.625 μg/mL) and found the strain to gain increasing susceptibility in a GWX dose-dependent manner. When co-treated with nafcillin and 0.625 μg/mL GWX, we detected a significant growth attenuation in Wt that was comparable to that displayed by nafcillin-treated Δ*stk1*, indicating that GWX rendered Wt susceptible to nafcillin. **(Fig. 3i)**. Δ*stk1* had similar growth patterns when treated with only nafcillin or with a combination of nafcillin and GWX, suggesting that the phenotype displayed above was specifically due to GWX-mediated inhibition of Stk1 function. To determine if the susceptibility caused by nafcillin and GWX in Wt mimicked the effect of *stk1* deletion, we performed qRT-PCR and immunoblotting to quantify *mecA* and PBP2a expression **(Figs. 3j-k, S2e)**. While Wt exposed to nafcillin displayed *mecA* induction **(Fig. 3j)** and increased PBP2a production **(Fig. 3k)**, exposure to nafcillin combined with GWX caused a significant reduction in levels of *mecA* and PBP2a. In alignment with findings of growth curve analysis **(Fig. 3i)**, diminished levels of *mecA* and PBP2a in Wt were comparable to those seen in nafcillin-treated-Δ*stk1*, confirming that inhibition of Stk1 by GWX mimicked the effect of *stk1* deletion. Since β-lactamase activity was reported to be attenuated in cultures induced by CBAP (2-(2'-carboxyphenyl)-benzoyl-6-aminopenicillanic acid) combined with kinase inhibitors[21], we explored the effect of nafcillin and GWX on *blaZ* induction using qRT-PCR and observed similar results to those seen by *mecA* **(Fig. S2f)**.

S*tk1* is required for efficient proteolysis of BlaI upon broad-spectrum β-lactam exposure

We next determined whether Stk1 affected the signal transduction step preceding *mecA* induction, namely the proteolysis of the transcriptional repressor BlaI[14,52] through immunoblotting

analysis **(Figs. 4a-c)**. Following the validation of a custom-generated BlaI antibody **(Figs. S3a-b)**, when untreated, we detected BlaI in similar amounts in our three isogenic strains, suggesting that deletion of *stk1* or *stp1* did not intrinsically alter its abundance **(Figs. 4a, S3c)**. Quantification of BlaI following exposure to nafcillin **(Figs. 4b, S3c)** or oxacillin **(Figs. 4c, S3c)** revealed that BlaI was highly diminished in the Wt and Δ*stp1* samples, but was largely intact in Δ*stk1*. Detection of a significant amount of intact BlaI in Δ*stk1* signified insufficient proteolysis, resulting in weakened *mecA* de-repression and broad-spectrum β-lactam susceptibility seen above **(Fig. 3)**. To associate insufficient BlaI cleavage with β-lactam susceptibility, we complemented Wt with an empty vector [E], wild-type *blaI* [Wt], or a non-cleavable mutant *blaI* [N101A and F102A] and assessed their response to nafcillin **(Figs. 4d-f)**. As the amino acid substitutions in Wt [*blaI* (N101A and F102A)] prevented proteolysis of BlaI by the sensor-inducer BlaR1[53], we detected intact BlaI in the strain when left untreated **(Fig. 4d, Fig. S3d)**, as well as when exposed to nafcillin **(Fig. 4e, Fig. S3d)** by immunoblotting. On the other hand, Wt complemented with *blaI* [Wt] showed efficient BlaI degradation as expected. Wt [*blaI* (N101A and F102A)] did not display growth alterations when untreated **(Fig. 4f)**; however, it was significantly susceptible to nafcillin compared to Wt [*blaI* (Wt)] in growth assays, as Wt [*blaI* (Wt)] successfully underwent BlaI proteolysis **(Fig. 4e)** and thereby survived in the presence of nafcillin. We also complemented Δ*stk1* with the BlaI variants for growth assays, and found that Δ*stk1* [*blaI* (Wt)] and Δ*stk1* [*blaI* (N101A and F102A)] were both susceptible to nafcillin **(Fig. 4f)**, suggesting that Stk1 function, as well as efficient BlaI proteolysis, were both crucial for β-lactam resistance. Furthermore, we found that nafcillin-treated Wt, Δ*stk1*, and Δ*stp1* samples had similar levels of *blaI* induction **(Fig. 4g)**, indicating that the BlaI degradation deficiency in Δ*stk1* was post-transcriptional in nature.

Stk1 is required for optimal BlaR1 presence in the bacterial cell membrane

BlaR1 is the polytopic membrane protein and sensor-inducer receptor that mediates the cleavage of BlaI[14,54]. To determine if attenuated BlaI proteolysis in Δ*stk1* was due to altered amounts of

BlaR1 prior to the detection of β-lactams, we performed immunoblotting assays with membrane fractions of our isogenic strains **(Figs. 5a-b)** following validation of a custom-generated BlaR1 antibody targeting the cytosolic protease helix **(Figs. S4a-d)**. We detected significantly reduced BlaR1 in Δ*stk1* compared to Wt at both the mid- **(Figs. 5a, S4e)** and late-exponential **(Figs. 5b, S4f)** growth phases, indicating that Stk1 is important for BlaR1 presence in the cell membrane. To further attribute the BlaR1 membrane localization defect to the loss of Stk1 function, we complemented Δ*stk1* with an empty vector [E], *stk1* [Wt], or with *stk1* [K39G] and observed that BlaR1 remained severely attenuated in the membrane fractions of Δ*stk1* [E] and Δ*stk1* [stk1 (K39G)]. Only the complementation with a functional Stk1 in Δ*stk1* [*stk1* (Wt)] enabled normal membrane levels of BlaR1 **(Figs. 5c, S5a)**, verifying that Stk1 promoted normal localization of BlaR1 into the membrane. Further, we used GWX to inhibit Stk1 in Wt and observed a drastic decrease in BlaR1 levels in the cell membrane **(Figs. 5d, S5b)**, substantiating that Stk1 function was vital for BlaR1 localization. In Δ*stp1*, BlaR1 levels were similar to that of Wt particularly at the late-exponential phase **(Fig. 5b)**. We complemented Δ*stp1* with an empty vector [E], *stp1* [Wt], and *stp1* [G40A] and saw that Δ*stp1* [*stp1* (Wt)] led to significant attenuation of BlaR1, whereas the absence of a functional Stp1 in Δ*stp1* [E] and Δ*stp1* [*stp1* (G40A)] was favorable for efficient BlaR1 localization in the membrane **(Fig. 5c)**. Stk1 and Stp1 thus had contrasting effects on BlaR1, as Stk1 promoted BlaR1 localization in the membrane, while Stp1 impeded it **(Figs. 5a-d)**. Remarkably, these alterations in membrane-anchored BlaR1 levels were detected in the absence of β-lactam exposure, suggesting that the impact of Stk1 and Stp1 functions on BlaR1 was independent of β-lactams.

Since our findings showed that BlaR1 was more severely attenuated in Δ*stk1* in late- and in mid-exponential phase **(Figs. 5a-b)**, we next questioned whether it was due to an altered expression of *blaR1*. On performing qRT-PCR, we observed that at the mid-exponential growth phase, *blaR1* was present in low but similar amounts in Wt, Δ*stk1*, and Δ*stp1*. At the late-exponential phase, *blaR1* transcripts were more abundant in all three strains compared to mid-exponential phase,

but it was significantly attenuated in Δ*stk1* compared to Wt and Δ*stp1* **(Fig. 5e)**. These findings suggest that Stk1 primarily modulates BlaR1 at the post-transcriptional level during mid-exponential growth. In the late-exponential phase, the observed increase in *blaR1* transcripts across strains likely reflects a leaky activation of the BlaR1-BlaI autoregulatory pathway[38]. In Δ*stk1*, impaired membrane localization of BlaR1 during mid-exponential growth may delay initiation of this autoregulatory loop, resulting in dampened *blaR1* expression later in growth. We confirmed this notion by assessing transcriptional and protein expression of BlaI. Similar to *blaR1*, *blaI* also displayed an overall increase in abundance in transcripts at the late-exponential phase **(Fig. S6a)**. In alignment with BlaR1, the abundance of *blaI* transcripts, as well as BlaI protein, was attenuated in Δ*stk1* **(Fig. S6a-c)**.

Stk1-mediated phosphorylation is required for facilitating membrane localization of BlaR1

BlaR1 is reported to sense β-lactams in the bacterial environment and undergo phosphorylation by Stk1[21], triggering subsequent signaling events leading to the induction of broad-spectrum β-lactam resistance. Since BlaR1 has been suggested to undergo phosphorylation at least at one tyrosine residue[21], we assessed the phosphorylation state of BlaR1 inserted into the membrane by probing it for phospho-tyrosine (P-tyrosine). We detected BlaR1 in Wt and Δ*stp1* when probed for P-tyrosine, demonstrating that the protein was phosphorylated at tyrosine residues **(Figs. 5f, S5c)**. Further, in alignment with previous results **(Figs. 5a-b)**, the significant reduction of phosphorylated BlaR1 in the membrane of Δ*stk1* suggested that phosphorylation of BlaR1 was vital for protein membrane localization **(Fig. 5f)**. Treatment of the Wt with the kinase inhibitor, GWX, led to a reduction in membrane-localized BlaR1, which was accompanied by a corresponding decrease in its phosphorylation **(Fig. 5d)**. These findings also revealed that phosphorylation of BlaR1 occurred independent of β-lactam exposure. These results together reiterated that Stk1-mediated phosphorylation was crucial for BlaR1 membrane localization.

We had difficulty being able to detect the reported autocleavage of BlaR1 following detection of β-lactam due to limited sensitivity of our Western blot assays. At the time that BlaI is being degraded (i.e., at 10 min after β-lactam induction), no discernable BlaR1 degradation fragment can be detected. Only until much later at 20 min after induction that enough BlaR1 degradation fragments are able to accumulate to be detectable via our assay, at which we are not able to detect a difference between the isogenic strains. The lack of difference seen at the later time point could be due to the induction of additional BlaR1 and the degradation fragments from said newly synthesized BlaR1 proteins.

Discussion

Resistance to broad-spectrum β-lactams in MRSA remains a global public health problem[37]. While various last-resort antibiotics are currently available to treat MRSA, owing to β-lactams' high efficacy and safety, efforts to re-sensitize MRSA to the antibiotic class are ongoing. Previous studies have highlighted the importance of BlaR1, the membrane-anchored, de facto sensory inducer of narrow-spectrum (BlaZ-mediated) β-lactam resistance, which, in addition, also controls broad-spectrum (*mecA*-mediated) β-lactam resistance in USA300 background strains of MRSA[53,55]. USA300 strains possess an intact, fully functional BlaZ regulatory system but bear a truncated *mecA* counterpart. Owing to a highly similar basis of regulation between the BlaZ and *mecA* regulatory systems, the expression of *mecA* in USA300 strains, in the absence of its cognate regulatory elements, is controlled via the BlaR1-BlaI pathway[14]. It is postulated that such uncanonical control of *mecA* expression enables the bacteria to mount a far superior and more effective broad-spectrum β-lactam resistance than its canonical counterpart (i.e., through MecR1-MecI)[56]. Since the *blaZ* and *mecA* regulatory systems in *S. aureus* are plasmid and genome (SCC*mec*) encoded, respectively, control of *mecA* expression in this manner exemplifies regulation of a core-genome element via a pathway that is plasmid encoded.

582 Even though the majority of the SCC*mec* clusters identified to date possess a truncated *mecA*
583 cluster[12], closely similar to that described above, the prevalence of such an uncanonical mode of
584 control of *mecA* expression among natural MRSA strains is unclear. It is particularly so, since it
585 is unknown how many strains with a truncated *mecA* cluster also possess the BlaZ regulatory
586 system, a prerequisite for such an uncanonical mode of broad-spectrum β-lactam resistance to
587 occur. To determine this, we analyzed all the genomic data entries of *S. aureus* strains available
588 in NCBI and examined them for the presence of genes mediating *blaZ* and *mecA* regulatory
589 pathways. Our results indicated that >75% of the ~78,000 MRSA genomic entries analyzed had
590 a truncated *mecA* cluster **(Fig. 1b)**. More importantly, >90% of ~60,000 entries for such MRSA
591 entries that had a truncated *mecA* cluster possessed the BlaZ regulatory system, highlighting the
592 fact that *mecA* expression in these strains is likely under the control of the BlaZ signaling system.
593 Interestingly, a much lower percentage of entries (~70% as opposed to 90%) of ~19,000 entries
594 for MRSA strains possessing an intact *mecA* cluster had the BlaZ regulatory system. The reason
595 for this decreased association of the BlaZ regulatory pathway among strains that had an intact
596 *mecA* counterpart is perhaps because the presence of both intact BlaZ and *mecA* regulatory
597 systems is unable to mount an effective response to produce β-lactam resistance[56]. Furthermore,
598 it is likely that broad-spectrum β-lactam resistance in certain MRSA strains with both intact *blaZ*
599 and *mecA* regulatory systems is also controlled by the BlaR1-BlaI pathway. A previous study
600 showing BlaR1-BlaI pathway-mediated control of *mecA* expression in a common hospital-
601 associated MRSA (CC5/ST5) strain with type II SCC*mec* provided an example of such a control
602 mechanism[14]. These results underscore that among the majority of natural MRSA isolates,
603 inducible expression of broad-spectrum β-lactam resistance is controlled by BlaZ regulatory
604 elements.
605 BlaR1 plays a pivotal role in the signal transduction process that enables a timely, cost-effective
606 response to β-lactam drugs for the production of drug resistance. Although a full understanding
607 of the mechanistic principles of the signaling pathway is currently lacking, previous studies have

608 shown that the sensory domain of BlaR1, upon recognition of β-lactam drugs in the bacterial
609 surroundings, undergoes conformational changes that propagate through the membrane helices
610 to the cytosolic facing protease domain, triggering cleavage of the BlaI repressor substrate, which
611 in turn enables de-repression of *blaZ* expression and production of drug resistance[14,53,54,57].
612 Recent studies have indicated that, of its many functions, the eSTK signaling pathway can
613 regulate broad-spectrum β-lactam resistance in *S. aureus*. The kinase component of the pathway,
614 Stk1, was previously associated with sensing β-lactams in the bacterial environment,
615 phosphorylation of BlaR1, and modulation of BlaZ-mediated narrow-spectrum β-lactam
616 resistance in *S. aureus*[21,56]. It was also shown to be involved in controlling broad-spectrum β-
617 lactam resistance in USA300 background strains through modulation of *mecA* expression[55]. The
618 basis through which eSTK exerted such roles in the bacteria was, however, unknown. In this
619 study, we demonstrated that Stk1-mediated phosphorylation of BlaR1 is essential for optimal
620 presence of BlaR1 in the bacterial membrane, allowing it to perform its transmembrane signaling
621 and regulatory role. Consequently, a loss of Stk1 function severely impaired BlaR1 levels in the
622 cell membrane, which in turn resulted in attenuated proteolytic cleavage of BlaI and *mecA* (as
623 well as *blaZ*) induction during β-lactam assault. Through the usage of robust genetic, biochemical,
624 and phenotypic assays in determining these results, we have also shown that both the function
625 and dose of Stk1 are important for the manifestation of broad-spectrum β-lactam resistance. Our
626 results demonstrated that Stk1-mediated BlaR1 phosphorylation likely occurs independent of β-
627 lactam treatment and that membrane levels of BlaR1 are coupled to its phosphorylation status.

628 Our immunoblotting assays suggested that Stk1 is likely a key mediator of BlaR1 phosphorylation.
629 We provided results that support the chemical inhibition of Stk1 by GWX potentiates synthetic
630 lethality to broad-spectrum β-lactams in MRSA strains lacking a functional MecI-MecR1 and
631 provided the structural basis for the potent inhibition of Stk1 by GWX. We substantiated our *in*
632 *vitro* data through an *in vivo* infection assay using *C. elegans*. Our results showed that worms

633 infected with Wt had increased survival when treated with nafcillin and GWX, compared to worms
634 treated with nafcillin only (**Fig. 6a)**. Increased survival of *C. elegans* infected with Δ*stk1* with
635 nafcillin, or Wt with nafcillin and GWX, indicated that targeting Stk1 could be beneficial to treat *S.*
636 *aureus* infections, particularly when used in combination with an established β-lactam drugs. In
637 addition to these, our results revealed the previously unknown role of Stp1, the cognate
638 phosphatase of the eSTK signaling pathway. Stp1 oppositely regulates BlaR1 phosphorylation
639 and membrane localization and consequently mediates a contrasting effect to that of StK1 in
640 mediating broad-spectrum β-lactam resistance.

641 **Outlook and limitations:**

642 In this study, we demonstrated that Stk1 mediated phosphorylation of BlaR1 is crucial for the
643 induction of broad-spectrum β-lactam resistance, and inhibition of Stk1 can re-sensitize MRSA
644 lacking a functional MecI-MecR1 to broad-spectrum β-lactams **(Fig. 6b)**. Our analysis suggested
645 that an approach that uses an effective Stk1 inhibitor as an adjuvant to produce synthetic lethality
646 to broad-spectrum β-lactams could be widely applicable to majority of the natural MRSA strains.
647 The high-resolution structure of Stk1-GWX inhibitory complex solved in this study will allow for
648 the design of derivatives that can be rationally modified to serve as more specific targets. GWX
649 was originally designed to target human CDK4 and was chosen for this study for its aqueous
650 solubility and relative potency compared to the other inhibitors screened.
651 We recognize that this study also has several limitations, which would need to be addressed in
652 the future. Firstly, BlaR1, being a polytopic transmembrane protein, is likely inserted into the
653 bacterial membrane co-translationally via the SecYEG section machinery and the associated
654 insertase, YidC[58]. Once inserted and folded into the membrane, it can be subjected to modification
655 by Stk1, which makes the cytosolic Zinc metalloprotease domain of BlaR1 the likely target of
656 phosphorylation. Currently, the the sites at which BlaR1 phosphorylation/s occurs are unknown.
657 Furthermore, the exact cause for the decreased abundance/localization of BlaR1 in the Δ*stk1*

also would need to be sorted out. Finally, the role played by Stp1 in β-lactam resistance needs to be resolved in further detail. Particularly, whether it solely dephosphorylates Stk1 or can it also dephosphorylate BlaR1 to mediate its function is unknown.

Acknowledgements

The authors thank the Electron Microscopy Core Imaging Facility, University of Maryland, Baltimore. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01AI165510 to SSC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Part of the research described in this paper was performed using beamline CMCF-BM at the Canadian Light Source, a national research facility of the University of Saskatchewan, which is supported by the Canada Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council (NSERC), the National Research Council (NRC), the Canadian Institutes of Health Research (CIHR), the Government of Saskatchewan, and the University of Saskatchewan. This research was also supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH authors were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

References

1 Lowy, F. D. Staphylococcus aureus infections. *N Engl J Med* **339**, 520-532, doi:10.1056/NEJM199808203390806 (1998).
2 Chambers, H. F. & Deleo, F. R. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature Publishing Group* **7**, 629-641, doi:10.1038/nrmicro2200 (2009).
3 Krupa, A. & Srinivasan, N. Diversity in domain architectures of Ser/Thr kinases and their homologues in prokaryotes. *BMC Genomics* **6**, 129, doi:10.1186/1471-2164-6-129 (2005).
4 Liebeke, M., Meyer, H., Donat, S., Ohlsen, K. & Lalk, M. A metabolomic view of Staphylococcus aureus and its ser/thr kinase and phosphatase deletion mutants: involvement in cell wall biosynthesis. *Chemistry & biology* **17**, 820-830, doi:10.1016/j.chembiol.2010.06.012 (2010).
5 Pensinger, D. A. *et al.* The Listeria monocytogenes PASTA Kinase PrkA and Its Substrate YvcK Are Required for Cell Wall Homeostasis, Metabolism, and Virulence. *PLoS Pathog* **12**, e1006001, doi:10.1371/journal.ppat.1006001 (2016).
6 Huemer, M. *et al.* Serine-threonine phosphoregulation by PknB and Stp contributes to quiescence and antibiotic tolerance in Staphylococcus aureus. *Sci Signal* **16**, eabj8194, doi:10.1126/scisignal.abj8194 (2023).
7 Tamber, S., Schwartzman, J. & Cheung, A. L. Role of PknB kinase in antibiotic resistance and virulence in community-acquired methicillin-resistant Staphylococcus aureus strain USA300. *Infect Immun* **78**, 3637-3646, doi:10.1128/iai.00296-10 (2010).
8 Chatterjee, A., Poon, R. & Chatterjee, S. S. Stp1 Loss of Function Promotes β-Lactam Resistance in Staphylococcus aureus That Is Independent of Classical Genes. *Antimicrob Agents Chemother* **64**, doi:10.1128/aac.02222-19 (2020).
9 Bush, K. & Bradford, P. A. β-Lactams and β-Lactamase Inhibitors: An Overview. *Cold Spring Harbor perspectives in medicine* **6**, doi:10.1101/cshperspect.a025247 (2016).
10 Chan, P. T. Nucleotide sequence of the Staphylococcus aureus PC1 beta-lactamase gene. *Nucleic acids research* **14**, 5940, doi:10.1093/nar/14.14.5940 (1986).
11 Herzberg, O. & Moult, J. Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.5 A resolution. *Science (New York, N.Y.)* **236**, 694-701, doi:10.1126/science.3107125 (1987).
12 Ito, T. *et al.* Staphylococcal Cassette Chromosome mec (SCCmec) analysis of MRSA. *Methods Mol Biol* **1085**, 131-148, doi:10.1007/978-1-62703-664-1_8 (2014).
13 Blázquez, B. *et al.* Regulation of the expression of the β-lactam antibiotic-resistance determinants in methicillin-resistant Staphylococcus aureus (MRSA). *Biochemistry* **53**, 1548-1550, doi:10.1021/bi500074w (2014).
14 Hackbarth, C. J. & Chambers, H. F. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. *Antimicrob Agents Chemother* **37**, 1144-1149, doi:10.1128/AAC.37.5.1144 (1993).
15 Hou, Z. *et al.* Co-blockade of mecR1/blaR1 signal pathway to restore antibiotic susceptibility in clinical isolates of methicillin-resistant Staphylococcus aureus. *Archives of medical science : AMS* **7**, 414-422, doi:10.5114/aoms.2011.23404 (2011).
16 Hanssen, A.-M. & Ericson Sollid, J. U. SCCmec in staphylococci: genes on the move. *FEMS Immunology & Medical Microbiology* **46**, 8-20, doi:10.1111/j.1574-695X.2005.00009.x (2006).
17 Patel, M. *et al.* USA300 Genotype Community-Associated Methicillin-Resistant Staphylococcus aureus as a Cause of Surgical Site Infections. *Journal of Clinical Microbiology* **45**, 3431-3433, doi:doi:10.1128/jcm.00902-07 (2007).
18 Uehara, Y. Current Status of Staphylococcal Cassette Chromosome mec (SCCmec). *Antibiotics (Basel, Switzerland)* **11**, doi:10.3390/antibiotics11010086 (2022).
19 Wang, W. *et al.* Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China. *Journal of Antimicrobial Chemotherapy* **77**, 903-909, doi:10.1093/jac/dkab500 (2022).

20 Martínez-Meléndez, A. *et al.* Staphylococcal Cassette Chromosome mec (SCCmec) in coagulase negative staphylococci. *Medicina Universitaria* **17**, 229-233, doi:10.1016/j.rmu.2015.10.003 (2015).

21 Boudreau, M. A., Fishovitz, J., Llarrull, L. I., Xiao, Q. & Mobashery, S. Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules. *ACS infectious diseases* **1**, 454-459, doi:10.1021/acsinfecdis.5b00086 (2015).

22 Bose, J. L., Fey, P. D. & Bayles, K. W. Genetic tools to enhance the study of gene function and regulation in Staphylococcus aureus. *Applied and environmental microbiology* **79**, 2218-2224, doi:10.1128/aem.00136-13 (2013).

23 Bae, T. & Schneewind, O. Allelic replacement in Staphylococcus aureus with inducible counter-selection. *Plasmid* **55**, 58-63, doi:10.1016/j.plasmid.2005.05.005 (2006).

24 Satishkumar, N., Lai, L. Y., Mukkayyan, N., Vogel, B. E. & Chatterjee, S. S. A Nonclassical Mechanism of β-Lactam Resistance in Methicillin-Resistant Staphylococcus aureus and Its Effect on Virulence. *Microbiology spectrum* **10**, e0228422, doi:10.1128/spectrum.02284-22 (2022).

25 (National Library of Medicine (US), National Center for Biotechnology Information, Bethesda (MD), 2025).

26 Camacho, C. *et al.* BLAST+: architecture and applications. *BMC Bioinformatics* **10**, 421, doi:10.1186/1471-2105-10-421 (2009).

27 Rakette, S., Donat, S., Ohlsen, K. & Stehle, T. Structural analysis of Staphylococcus aureus serine/threonine kinase PknB. *PLoS One* **7**, e39136, doi:10.1371/journal.pone.0039136 (2012).

28 Kabsch, W. XDS. *Acta crystallographica. Section D, Biological crystallography* **66**, 125-132, doi:10.1107/s0907444909047337 (2010).

29 Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? *Acta crystallographica. Section D, Biological crystallography* **69**, 1204-1214, doi:10.1107/S0907444913000061 (2013).

30 Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta crystallographica. Section D, Biological crystallography* **67**, 235-242, doi:10.1107/s0907444910045749 (2011).

31 Tickle, I. J., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., Bricogne, G. *STARANISO anisotropy & Bayesian estimation server (https://staraniso.globalphasing.org/cgi-bin/staraniso.cgi)*, 2016).

32 McCoy, A. J. *et al.* Phaser crystallographic software. *Journal of applied crystallography* **40**, 658-674, doi:10.1107/s0021889807021206 (2007).

33 Adams, P. D. *et al.* PHENIX: building new software for automated crystallographic structure determination. *Acta crystallographica. Section D, Biological crystallography* **58**, 1948-1954, doi:10.1107/s0907444902016657 (2002).

34 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta crystallographica. Section D, Biological crystallography* **66**, 486-501, doi:10.1107/s0907444910007493 (2010).

35 Chen, V. B. *et al.* MolProbity: all-atom structure validation for macromolecular crystallography. *Acta crystallographica. Section D, Biological crystallography* **66**, 12-21, doi:10.1107/s0907444909042073 (2010).

36 Schrödinger, L. a. D., W. . *PyMOL*.

37 Murray, C. J. L. *et al.* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* **399**, 629-655, doi:10.1016/S0140-6736(21)02724-0 (2022).

38 Llarrull, L. I., Toth, M., Champion, M. M. & Mobashery, S. Activation of BlaR1 protein of methicillin-resistant Staphylococcus aureus, its proteolytic processing, and recovery from induction of resistance. *J Biol Chem* **286**, 38148-38158, doi:10.1074/jbc.M111.288985 (2011).

39 Janczarek, M., Vinardell, J. M., Lipa, P. & Karaś, M. Hanks-Type Serine/Threonine Protein Kinases and Phosphatases in Bacteria: Roles in Signaling and Adaptation to Various Environments. *International journal of molecular sciences* **19**, doi:10.3390/ijms19102872 (2018).

40 Debarbouille, M. *et al.* Characterization of a serine/threonine kinase involved in virulence of Staphylococcus aureus. *J Bacteriol* **191**, 4070-4081, doi:10.1128/JB.01813-08 (2009).

41 Oh, D. H. *et al.* Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study. *BMC infectious diseases* **18**, 60, doi:10.1186/s12879-018-2978-z (2018).

42 Schweizer, M. L. *et al.* Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. *BMC infectious diseases* **11**, 279, doi:10.1186/1471-2334-11-279 (2011).

43 Rao, S. N. *et al.* Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. *Antimicrob Agents Chemother* **59**, 5232-5238, doi:10.1128/aac.04677-14 (2015).

44 Zheng, W. *et al.* Structure-Based Identification of a Potent Inhibitor Targeting Stp1-Mediated Virulence Regulation in Staphylococcus aureus. *Cell Chemical Biology* **23**, 1002-1013, doi:https://doi.org/10.1016/j.chembiol.2016.06.014 (2016).

45 Schaenzer, A. J. *et al.* GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus. *ACS infectious diseases* **4**, 1508-1518, doi:10.1021/acsinfecdis.8b00136 (2018).

46 Charter, N. W., Kauffman, L., Singh, R. & Eglen, R. M. A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5'-diphosphate accumulation. *Journal of biomolecular screening* **11**, 390-399, doi:10.1177/1087057106286829 (2006).

47 McClendon, C. L., Kornev, A. P., Gilson, M. K. & Taylor, S. S. Dynamic architecture of a protein kinase. *Proceedings of the National Academy of Sciences* **111**, E4623-E4631, doi:doi:10.1073/pnas.1418402111 (2014).

48 Vijayan, R. S. *et al.* Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. *Journal of medicinal chemistry* **58**, 466-479, doi:10.1021/jm501603h (2015).

49 Ung, P. M. & Schlessinger, A. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. *ACS chemical biology* **10**, 269-278, doi:10.1021/cb500696t (2015).

50 Taylor, S. S. & Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins. *Trends in biochemical sciences* **36**, 65-77, doi:10.1016/j.tibs.2010.09.006 (2011).

51 Modi, V. & Dunbrack, R. L., Jr. Defining a new nomenclature for the structures of active and inactive kinases. *Proc Natl Acad Sci U S A* **116**, 6818-6827, doi:10.1073/pnas.1814279116 (2019).

52 Safo, M. K. *et al.* Crystal structures of the BlaI repressor from Staphylococcus aureus and its complex with DNA: insights into transcriptional regulation of the bla and mec operons. *J Bacteriol* **187**, 1833-1844, doi:10.1128/jb.187.5.1833-1844.2005 (2005).

53 Zhang, H. Z., Hackbarth, C. J., Chansky, K. M. & Chambers, H. F. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. *Science (New York, N.Y.)* **291**, 1962-1965, doi:10.1126/science.1055144 (2001).

54 Alexander, J. A. N. *et al.* Structural basis of broad-spectrum β-lactam resistance in Staphylococcus aureus. *Nature* **613**, 375-382, doi:10.1038/s41586-022-05583-3 (2023).

55 Cutrona, N. *et al.* From Antihistamine to Anti-infective: Loratadine Inhibition of Regulatory PASTA Kinases in Staphylococci Reduces Biofilm Formation and Potentiates β-Lactam Antibiotics and Vancomycin in Resistant Strains of Staphylococcus aureus. *ACS infectious diseases* **5**, 1397-1410, doi:10.1021/acsinfecdis.9b00096 (2019).

831 56 McKinney, T. K., Sharma, V. K., Craig, W. A. & Archer, G. L. Transcription of the gene
832 mediating methicillin resistance in Staphylococcus aureus (mecA) is corepressed but not
833 coinduced by cognate mecA and beta-lactamase regulators. *J Bacteriol* **183**, 6862-6868,
834 doi:10.1128/jb.183.23.6862-6868.2001 (2001).
835 57 Lim, D. & Strynadka, N. C. Structural basis for the beta lactam resistance of PBP2a from
836 methicillin-resistant Staphylococcus aureus. *Nature structural biology* **9**, 870-876,
837 doi:10.1038/nsb858 (2002).
838 58 Freudl, R. Leaving home ain't easy: protein export systems in Gram-positive bacteria. *Res*
839 *Microbiol* **164**, 664-674, doi:10.1016/j.resmic.2013.03.014 (2013).

840

841

Figure legends

Figure 1. Stk1 is essential for β-lactam resistance.

a) Schematic representation of the classical resistance pathway of β-lactam resistance. In contemporary *S. aureus* strains, both narrow- and broad-spectrum β-lactam resistance, mediated by β-lactamase (BlaZ) and the low β-lactam affinity Penicillin Binding Protein (PBP2a), respectively, are controlled via the BlaR1-BlaI response regulatory pathway. The mechanistic role of the STK signaling pathway, which is comprised of the kinase (Stk1) and phosphatase (Stp1) in mediating β-lactam resistance, will be deciphered in this study.

b) Assessment of all available NCBI *S. aureus* genomic sequences reveals that in a majority of MRSA entries, *mecA* expression is controlled via the BlaR1-BlaI pathway, as they likely lacked a functional MecR1-MecI regulatory pathway, as 75.90% of entries did not possess the *mecI* gene. (+) indicates presence of specified genes, (-) indicates absence of specified genes.

c & d) Immunoblotting of SF8300 and its isogenic *stk1* and *stp1* deletion strains. Hourly probing for basal **c)** Stp1 in whole cell lysates and **d)** Stk1 in membrane fractions over 5 hours of growth. Sortase A (SrtA) was used as a loading control for the Stk1 immunoblot.

e) Growth curve assay and CFU enumeration of *S. aureus* SF8300 Wt (blue circles) and its isogenic Δ*stk1* (red circles) and Δ*stp1* (beige circles) mutants without β-lactams (untreated), or with nafcillin ([Naf] 2 µg/mL) or oxacillin ([Oxa] 4 µg/mL). CFU was measured at 12 hours.

f) Electron microscopy images of *S. aureus* SF8300 Wt and its isogenic Δ*stk1* and Δ*stp1* mutants without (untreated) and with β-lactam treatment (treated).

Growth curve assays and CFU enumeration were performed in triplicate, in two independent experiments. Data from an independent experiment are presented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 2. Deletion of *stk1* induces synthetic lethality to β-lactams

a & b) Immunoblotting of Δ*stk1* complemented with an empty vector [E], wild-type *stk1* [Wt] or a functionally defective mutant *stk1* [K39G] and Δ*stp1* complemented with an empty vector [E], wild-type *stp1* [Wt] or a functional mutant *stp1* [G40A] at the late-exponential stage (3 hours of growth), **a)** probing for basal Stk1 in membrane fractions and **b)** probing for basal Stp1 in whole cell lysates. Sortase A (SrtA) was used as a loading control for the Stk1 immunoblot.

c) Growth curve assay and CFU enumeration for Δ*stk1* strain complemented with constitutively expressing empty vector [E] (red circles), *stk1* [Wt] (white circles, red border) or with *stk1* [K39G] (grey circles, red border) when untreated, or treated with 2 µg/mL nafcillin or 4 µg/mL oxacillin. CFU was measured at 12 hours.

d) Growth curve assay for Wt and Δ*stk1* complemented with xylose-inducible empty vector [E], *stk1* [Wt] or *stk1* [K39G]. In untreated conditions, Wt [E] was supplemented with 0% (blue circles) or 0.2% xylose (blue squares). Δ*stk1* complemented with empty vector [E] (red symbols), *stk1* [Wt] (white symbols, red border), or *stk1* [K39G] (white symbols, grey border) were supplemented with 0% xylose (circles) or 0.2% xylose (squares). Under 2 µg/mL nafcillin treatment, Wt [E] (blue circles) and Δ*stk1* [E] (red circles) were cultured without xylose (0%). Δ*stk1* complemented with *stk1* [Wt] was supplemented with varying concentrations of xylose, including 0% (white circles, red border), 0.05% (white squares, purple border), 0.1% (white squares, blue border), and 0.2% (white squares, red border). Δ*stk1* complemented with *stk1* [K39G] was supplemented with 0.2% xylose (white squares, grey border).

e) Growth curve assay and CFU enumeration for Δ*stp1* complemented with constitutively expressing empty vector [E] (beige circles), *stp1* [Wt] (while circles, beige border) or with the *stp1* [G40A] (grey circles, beige border), untreated, or with 2 µg/mL nafcillin or 4 µg/mL oxacillin. CFU was measured at 12 hours.

Growth assays and CFU enumeration were performed in triplicate, in two independent experiments. Data from an independent experiment are presented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 3. *Stk1* is required for efficient induction of *mecA* during β-lactam exposure

a & b) qRT-PCR for relative induction of *mecA* in Wt, Δ*stk1*, and Δ*stp1* at the mid-exponential stage (2 hours of growth) when treated with **a)** 2 µg/mL nafcillin for 30 min or **(b)** 4 µg/mL oxacillin for 30 min in comparison to samples untreated for 30 min. qRT-PCR for *mecA* was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD.

c - e) Immunoblotting and corresponding densitometry analysis for PBP2a induction in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at the mid-exponential stage (2 hours of growth), **c)** without β-lactam exposure, **d)** with exposure to 2 µg/mL nafcillin for 1 hour, or **e)** with exposure to 4 µg/mL oxacillin for 1 hour. Control in **c)** represents Wt at the mid-exponential stage (2 hours of growth) treated with 2 µg/mL nafcillin for 1 hour. Sortase A (SrtA) was used as a loading control.

f) Dose-response curve of GW779439X (GWX) inhibitor against Stk1 kinase *in vitro* using ADP-Quest assay kit.

g) The overall structure of $Stk1^{1-291}$ highlighting the bilobal nature of the kinase domain. The GWX ligand occupies the cleft between the N- and C-lobes of the kinase domain. Key structural features involved in the activation and deactivation of the enzyme are also labelled. Additional GWX ligand molecules involved in crystal packing have been hidden for clarity.

h) 3D-representation of the interactions between GWX and key residues in $Stk1^{1-291}$, including pi-stacking interactions between the centroids of F150 and the pyrazolopyridine moiety of the GWX ligand.

i) Growth assay demonstrating the effect of the GWX inhibitor without or with 2 µg/mL nafcillin. In untreated conditions, Wt (blue) and Δ*stk1* (red) were growth without (circles) or with 0.625 µg/mL GWX (squares). With nafcillin treatment, Wt was treated with GWX in increasing concentrations: 0 µg/mL (dark blue circles), 0.078 µg/mL (pink squares), 0.156 µg/mL (light blue squares), 0.313 µg/mL (orange squares), and 0.625 µg/mL (dark blue squares).

(j) qRT-PCR for relative induction of *mecA* in Wt and Δ*stk1* at the mid-exponential stage (2 hours of growth) when treated with 2 µg/mL nafcillin (Naf), 2.5 µg/mL GWX inhibitor, or co-treated with nafcillin and GWX inhibitor for 30 min in comparison to samples untreated for 30 min.

(k) Immunoblotting and corresponding densitometry for PBP2a induction in Wt and Δ*stk1* in membrane fractions at the mid-exponential stage (2 hours of growth) when treated with 2 µg/mL nafcillin (Naf), 2.5 µg/mL GWX inhibitor, or co-treated with nafcillin and GWX inhibitor for 60 min. Sortase A (SrtA) was used as a loading control.

Immunoblotting was performed in three independent experiments, the blots of which were used for densitometry, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 4: Stk1 function is required for efficient proteolysis of BlaI

a - c) Immunoblotting and corresponding densitometry analysis of intact BlaI in Wt, Δ*stk1*, and Δ*stp1* in whole cell lysates at mid-exponential stage (2 hours of growth), **a)** when untreated, **b)** with 10 min exposure to 2 µg/mL nafcillin or **c)** with 10 min exposure to 4 µg/mL oxacillin. Sortase A (SrtA) was used as a loading control.

d & e) Immunoblotting of intact BlaI in Wt [E], Wt with overexpressed *blaI* [Wt], and Wt with overexpressed non-cleavable mutant *blaI* [N101A, F102A] in whole cell lysates at mid-exponential stage (2 hours of growth), **d)** when untreated, **e)** or with 1 h exposure to 2 µg/mL nafcillin. Sortase A (SrtA) was used as a loading control.

f) Growth assay without and with 2 µg/mL nafcillin, determining the role of BlaI degradation in β-lactam resistance. Wt (blue circles) and isogenic Δ*stk1* (red circles) were complemented with an empty vector [E] (full circles), wild-type *blaI* [Wt] (white circles) or, with non-cleavable mutant *blaI* [N101A, F102A].

g) qRT-PCR for relative fold change in *blaI* expression in Wt, Δ*stk1*, and Δ*stp1* at mid-exponential stage (2 hours of growth) with 2 µg/mL nafcillin treatment for 30 min in comparison to samples untreated for 30 min.

qRT-PCR was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD. Immunoblotting was performed in three independent experiments, the blots of which were used for densitometry, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 5: Stk1-mediated phosphorylation is required for efficient localization of BlaR1 into the cell membrane.

a & b) Immunoblotting and corresponding densitometry analysis for basal BlaR1 protein levels in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at **a)** the mid-exponential stage (2 hours of growth) and **b)** the late-exponential stage (3 hours of growth). Sortase A (SrtA) was used as a loading control.

c) Immunoblotting for basal levels of BlaR1 in Δ*stk1* and Δ*stp1* strains complemented with an empty vector [E] and corresponding wild type [Wt] or functionally inactive *stk1* [K39G] or *stp1* [G40A] membrane fractions at late-exponential stage (3 hours of growth). Sortase A (SrtA) was used as a loading control.

d) Immunoblotting and corresponding densitometry analysis of basal BlaR1 in Wt and Δ*stk1* membrane fractions at late-exponential stage (3 hours of growth) without and with 1 h GWX treatment. In addition to probing for BlaR1 (α-BlaR1, green bands), samples were also probed for phospho-tyrosine (α-P-tyrosine, red bands) to determine protein phosphorylation. Overlay (yellow bands) represents signals obtained for both α-BlaR1 and α-P-tyrosine. Sortase A (SrtA) was used as a loading control.

e) qRT-PCR for basal *blaR1* expression in Wt, Δ*stk1*, and Δ*stp1* at the mid-exponential stage (2 hours of growth) and late-exponential stage (3 hours of growth). qRT-PCR was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD.

f) Immunoblotting of basal phosphorylation of BlaR1 in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at late-exponential stage (3 hours of growth). Samples were probed for BlaR1 (α-BlaR1, green bands), Phospho-tyrosine (α-P-tyrosine, red bands). Overlay (yellow bands) represents signals obtained for both α-BlaR1 and α-P-tyrosine. Sortase A (SrtA) was used as a loading control.

Densitometry analysis are the product of three independent experiments, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 6:

a) Nafcillin and GWX co-treatment increases the survival of MRSA-infected *C. elegans*. Survival assay of *C. elegans* infected with Wt and Δ*stk1* with or without treatment, at 72 hours. Treatment was carried out either with 2 µg/mL nafcillin, 2.5 µg/mL GWX, or co-treated with both nafcillin and GWX.

b) Summary of findings. In USA300 and contemporary clinical strains, where broad-spectrum β-lactam resistance is attributed to the BlaR1-BlaI pathway, inhibition of Stk1 function results in β-lactam susceptibility, making Stk1 a promising therapeutic target. The loss of Stk1 (right panel) hampers the phosphorylation of BlaR1, precluding it from being efficiently incorporated into the cell membrane. On β-lactam exposure, the ability of BlaR1 to successfully mediate signal transduction to cause cleavage of the BlaI repressor was impaired, resulting in attenuated de-repression of *mecA*, which in turn decreases expression of PBP2a, culminating in β-lactam susceptibility.

Fig 1



a
β-lactams
Resistance
β lactamase
Extracellular space
Sensory domain
PASTA domains
Cell wall
BlaR1
PBP2a
Stk1
Cell Membrane
Zn2+
ZnMP
?
Kinase domain
ATP
ADP
Target proteins
Phosphorylation
BlaI degradation
Stp1
ΔmecR1
MecA
BlaI
ψIS
Genome
PBP2a
mRNA
Cytosol
β lactamase
BlaZ
BlaI
BlaR1
BlaI
Plasmid
b
S. aureus 100% n=127,894
77.98% blaZ (+) blaI (+) n=99,736
stp1-stk1 (+) 99.71% n=127,522
78.04% blaZ (+) blaI (+) n=99,514
MSSA, mecA (-) 38.66% n=49,305
66.70% blaZ (+) blaI (+) n=32,884
MRSA, mecA (+) 61.34% n=78,217
85.19% blaZ (+) blaI (+) n=66,630
MRSA, mecI (-) 75.90% n=59,370
90.27% blaZ (+) blaI (+) n=53,594
MRSA, mecI (+) 24.10% n=18,847
69.17% blaZ (+) blaI (+) n=13,036
Kinase
TM
3X PASTA
Ig-like
USA300HOU_1155
stp1
stk1
engC
c
2h
3h
4h
5h
kDa
L
Wt
Δstk1
Δstp1
25–
α-Stp1
d
kDa
75–
25–
α-Stk1
α-SrtA
e
Untreated
[Naf] 2 μg/mL
[Oxa] 4 μg/mL
OD600
Time (h)
Wt
Δstk1
Δstp1
Log CFU/mL
ns
****
*
f
Wt
Δstk1
Δstp1
Untreated
Treated

Figure 1. Stk1 is essential for β-lactam resistance.

a) Schematic representation of the classical resistance pathway of β-lactam resistance. In contemporary *S. aureus* strains, both narrow- and broad-spectrum β-lactam resistance, mediated by β-lactamase (BlaZ) and the low β-lactam affinity Penicillin Binding Protein (PBP2a), respectively, are controlled via the BlaR1-BlaI response regulatory pathway. The mechanistic role of the STK signaling pathway, which is comprised of the kinase (Stk1) and phosphatase (Stp1) in mediating β-lactam resistance, will be deciphered in this study.

b) Assessment of all available NCBI *S. aureus* genomic sequences reveals that in a majority of MRSA entries, *mecA* expression is controlled via the BlaR1-BlaI pathway, as they likely lacked a functional MecR1-MecI regulatory pathway, as 75.90% of entries did not possess the *mecI* gene. (+) indicates presence of specified genes, (-) indicates absence of specified genes.

c & d) Immunoblotting of SF8300 and its isogenic *stk1* and *stp1* deletion strains. Hourly probing for basal **c)** Stp1 in whole cell lysates and **d)** Stk1 in membrane fractions over 5 hours of growth. Sortase A (SrtA) was used as a loading control for the Stk1 immunoblot.

e) Growth curve assay and CFU enumeration of *S. aureus* SF8300 Wt (blue circles) and its isogenic Δ*stk1* (red circles) and Δ*stp1* (beige circles) mutants without β-lactams (untreated), or with nafcillin ([Naf] 2 μg/mL) or oxacillin ([Oxa] 4 μg/mL). CFU was measured at 12 hours.

f) Electron microscopy images of *S. aureus* SF8300 Wt and its isogenic Δ*stk1* and Δ*stp1* mutants without (untreated) and with β-lactam treatment (treated).

Growth curve assays and CFU enumeration were performed in triplicate, in two independent experiments. Data from an independent experiment are presented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Fig 2



a
Δstk1
Δstp1
kDa
L
[E]
[Wt]
[K39G]
[E]
[Wt]
[G40A]
75–
25–
α-Stk1
α-SrtA
b
Δstk1
Δstp1
kDa
L
[E]
[Wt]
[K39G]
[E]
[Wt]
[G40A]
25–
α-Stp1
c
Untreated
[Naf] 2 µg/mL
[Oxa] 4 µg/mL
OD600
Time (h)
Log CFU/mL
Δstk1
E
stk1(Wt)
stk1(K39G)
ns
****
**
d
Untreated
[Naf] 2 µg/mL
OD600
Time (h)
Wt
Xylose (%)
E 0
E 0.2
Δstk1
E 0
E 0.2
stk1(Wt) 0
stk1(Wt) 0.2
stk1(K39G) 0
stk1(K39G) 0.2
E 0
Δstk1
E 0
stk1(Wt) 0
stk1 (Wt) 0.05
stk1 (Wt) 0.1
stk1 (Wt) 0.2
stk1 (K39G) 0.2
e
Untreated
[Naf] 2 µg/mL
[Oxa] 4 µg/mL
OD600
Time (h)
Log CFU/mL
Δstp1
E
stp1(Wt)
stp1(G40A)
ns
****

Figure 2. Deletion of *stk1* induces synthetic lethality to β-lactams

a & b) Immunoblotting of Δ*stk1* complemented with an empty vector [E], wild-type *stk1* [Wt] or a functionally defective mutant *stk1* [K39G] and Δ*stp1* complemented with an empty vector [E], wild-type *stp1* [Wt] or a functional mutant *stp1* [G40A] at the late-exponential stage (3 hours of growth), **a)** probing for basal Stk1 in membrane fractions and **b)** probing for basal Stp1 in whole cell lysates. Sortase A (SrtA) was used as a loading control for the Stk1 immunoblot.

c) Growth curve assay and CFU enumeration for Δ*stk1* strain complemented with constitutively expressing empty vector [E] (red circles), *stk1* [Wt] (white circles, red border) or with *stk1* [K39G] (grey circles, red border) when untreated, or treated with 2 µg/mL nafcillin or 4 µg/mL oxacillin. CFU was measured at 12 hours.

d) Growth curve assay for Wt and Δ*stk1* complemented with xylose-inducible empty vector [E], *stk1* [Wt] or *stk1* [K39G]. In untreated conditions, Wt [E] was supplemented with 0% (blue circles) or 0.2% xylose (blue squares). Δ*stk1* complemented with empty vector [E] (red symbols), *stk1* [Wt] (white symbols, red border), or *stk1* [K39G] (white symbols, grey border) were supplemented with 0% xylose (circles) or 0.2% xylose (squares). Under 2 µg/mL nafcillin treatment, Wt [E] (blue circles) and Δ*stk1* [E] (red circles) were cultured without xylose (0%). Δ*stk1* complemented with *stk1* [Wt] was supplemented with varying concentrations of xylose, including 0% (white circles, red border), 0.05% (white squares, purple border), 0.1% (white squares, blue border), and 0.2% (white squares, red border). Δ*stk1* complemented with *stk1* [K39G] was supplemented with 0.2% xylose (white squares, grey border).

e) Growth curve assay and CFU enumeration for Δ*stp1* complemented with constitutively expressing empty vector [E] (beige circles), *stp1* [Wt] (while circles, beige border) or with the *stp1* [G40A] (grey circles, beige border), untreated, or with 2 µg/mL nafcillin or 4 µg/mL oxacillin. CFU was measured at 12 hours.

Growth assays and CFU enumeration were performed in triplicate, in two independent experiments. Data from an independent experiment are presented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Fig 3



a
b
c
d
e
f
g
h
i
j
k
mecA Fold Change (Treated/Untreated)
Wt
Δstk1
Δstp1
control
kDa
L
75
25
α-PBP2a
α-SrtA
Relative Abundance (AU)
Control
100nM Stk1
IC50: 188.5 nM
% Inhibition
[GWX] nM
N-Lobe
C-Lobe
GWX
Glycine-Rich Loop
(18-25)
DFG Motif
(151-153)
Activation Loop
(160-171)
β1
β2
β3
β4
β5
β7
β8
αC
αD
αE
αF
αG
αH
F150
I90
E97
K39
3.9A
3.1A
3.0A
2.9A
Untreated
[Naf] 2 μg/mL
OD600
Time (h)
[GWX] μg/mL
[Naf] 2 μg/mL
[GWX] 2.5 μg/mL
ns

Figure 3. *Stk1* is required for efficient induction of *mecA* during β-lactam exposure

a & b) qRT-PCR for relative induction of *mecA* in Wt, Δ*stk1*, and Δ*stp1* at the mid-exponential stage (2 hours of growth) when treated with **a)** 2 µg/mL nafcillin for 30 min or **(b)** 4 µg/mL oxacillin for 30 min in comparison to samples untreated for 30 min. qRT-PCR for *mecA* was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD.

c - e) Immunoblotting and corresponding densitometry analysis for PBP2a induction in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at the mid-exponential stage (2 hours of growth), **c)** without β-lactam exposure, **d)** with exposure to 2 µg/mL nafcillin for 1 hour, or **e)** with exposure to 4 µg/mL oxacillin for 1 hour. Control in **c)** represents Wt at the mid-exponential stage (2 hours of growth) treated with 2 µg/mL nafcillin for 1 hour. Sortase A (SrtA) was used as a loading control.

f) Dose-response curve of GW779439X (GWX) inhibitor against Stk1 kinase *in vitro* using ADP-Quest assay kit.

g) The overall structure of $Stk1^{1-291}$ highlighting the bilobal nature of the kinase domain. The GWX ligand occupies the cleft between the N- and C-lobes of the kinase domain. Key structural features involved in the activation and deactivation of the enzyme are also labelled. Additional GWX ligand molecules involved in crystal packing have been hidden for clarity.

h) 3D-representation of the interactions between GWX and key residues in $Stk1^{1-291}$, including pi-stacking interactions between the centroids of F150 and the pyrazolopyridine moiety of the GWX ligand.

i) Growth assay demonstrating the effect of the GWX inhibitor without or with 2 µg/mL nafcillin. In untreated conditions, Wt (blue) and Δ*stk1* (red) were growth without (circles) or with 0.625 µg/mL GWX (squares). With nafcillin treatment, Wt was treated with GWX in increasing concentrations: 0 µg/mL (dark blue circles), 0.078 µg/mL (pink squares), 0.156 µg/mL (light blue squares), 0.313 µg/mL (orange squares), and 0.625 µg/mL (dark blue squares).

(j) qRT-PCR for relative induction of *mecA* in Wt and Δ*stk1* at the mid-exponential stage (2 hours of growth) when treated with 2 µg/mL nafcillin (Naf), 2.5 µg/mL GWX inhibitor, or co-treated with nafcillin and GWX inhibitor for 30 min in comparison to samples untreated for 30 min.

(k) Immunoblotting and corresponding densitometry for PBP2a induction in Wt and Δ*stk1* in membrane fractions at the mid-exponential stage (2 hours of growth) when treated with 2 µg/mL nafcillin (Naf), 2.5 µg/mL GWX inhibitor, or co-treated with nafcillin and GWX inhibitor for 60 min. Sortase A (SrtA) was used as a loading control.

Immunoblotting was performed in three independent experiments, the blots of which were used for densitometry, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Fig 4



a
b
c
d
e
f
g
kDa
L
Wt
Δstk1
Δstp1
15
25
α-BlaI
α-SrtA
Relative Abundance (AU)
ns
*
***
**
Wt
Δstk1
Δstp1
Wt [Untreated]
[E]
[Wt]
[N101A, F102A]
Wt [Naf] 2 µg/mL
Untreated
[Naf] 2 µg/mL
OD600
Time (h)
Wt
E
BlaI (Wt)
BlaI (N101A,F102A)
Δstk1
bla1 Fold Change (Treated/Untreated)

Figure 4: Stk1 function is required for efficient proteolysis of BlaI

a - c) Immunoblotting and corresponding densitometry analysis of intact BlaI in Wt, Δ*stk1*, and Δ*stp1* in whole cell lysates at mid-exponential stage (2 hours of growth), **a)** when untreated, **b)** with 10 min exposure to 2 µg/mL nafcillin or **c)** with 10 min exposure to 4 µg/mL oxacillin. Sortase A (SrtA) was used as a loading control.

d & e) Immunoblotting of intact BlaI in Wt [E], Wt with overexpressed *blaI* [Wt], and Wt with overexpressed non-cleavable mutant *blaI* [N101A, F102A] in whole cell lysates at mid-exponential stage (2 hours of growth), **d)** when untreated, **e)** or with 1 h exposure to 2 µg/mL nafcillin. Sortase A (SrtA) was used as a loading control.

f) Growth assay without and with 2 µg/mL nafcillin, determining the role of BlaI degradation in β-lactam resistance. Wt (blue circles) and isogenic Δ*stk1* (red circles) were complemented with an empty vector [E] (full circles), wild-type *blaI* [Wt] (white circles) or, with non-cleavable mutant *blaI* [N101A, F102A].

g) qRT-PCR for relative fold change in *blaI* expression in Wt, Δ*stk1*, and Δ*stp1* at mid-exponential stage (2 hours of growth) with 2 µg/mL nafcillin treatment for 30 min in comparison to samples untreated for 30 min.

qRT-PCR was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD. Immunoblotting was performed in three independent experiments, the blots of which were used for densitometry, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Fig 5



a
membrane
kDa
L
Wt
Δstk1
Δstp1
50
25
membrane
Relative Abundance (AU)
****
****
ns
b
membrane
ns
*
*
Wt
Δstk1
Δstp1
c
Δstk1
Δstp1
[E]
[Wt]
[K39G]
[E]
[Wt]
[G40A]
α-BlaR1
α-SrtA
d
0
2.5
GWX [μg/mL]
α-BlaR1
α-P-tyrosine
overlay
α-SrtA
***
***
[GWX] μg/mL
Wt 0
Δstk1 0
Wt 2.5
Δstk1 2.5
α-BlaR1
α-P-Tyr
e
2h
3h
blaR1 Expression (untreated)
ns
ns ns
**
****
*
f
membrane
α-BlaR1
α-P-tyrosine
overlay
α-SrtA

Figure 5: Stk1-mediated phosphorylation is required for efficient localization of BlaR1 into the cell membrane.

a & b) Immunoblotting and corresponding densitometry analysis for basal BlaR1 protein levels in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at **a)** the mid-exponential stage (2 hours of growth) and **b)** the late-exponential stage (3 hours of growth). Sortase A (SrtA) was used as a loading control.

c) Immunoblotting for basal levels of BlaR1 in Δ*stk1* and Δ*stp1* strains complemented with an empty vector [E] and corresponding wild type [Wt] or functionally inactive *stk1* [K39G] or *stp1* [G40A] membrane fractions at late-exponential stage (3 hours of growth). Sortase A (SrtA) was used as a loading control.

d) Immunoblotting and corresponding densitometry analysis of basal BlaR1 in Wt and Δ*stk1* membrane fractions at late-exponential stage (3 hours of growth) without and with 1 h GWX treatment. In addition to probing for BlaR1 (α-BlaR1, green bands), samples were also probed for phospho-tyrosine (α-P-tyrosine, red bands) to determine protein phosphorylation. Overlay (yellow bands) represents signals obtained for both α-BlaR1 and α-P-tyrosine. Sortase A (SrtA) was used as a loading control.

e) qRT-PCR for basal *blaR1* expression in Wt, Δ*stk1*, and Δ*stp1* at the mid-exponential stage (2 hours of growth) and late-exponential stage (3 hours of growth). qRT-PCR was performed in triplicate, in two independent experiments. Data from representative independent experiments are presented as mean ± SD.

f) Immunoblotting of basal phosphorylation of BlaR1 in Wt, Δ*stk1*, and Δ*stp1* membrane fractions at late-exponential stage (3 hours of growth). Samples were probed for BlaR1 (α-BlaR1, green bands), Phospho-tyrosine (α-P-tyrosine, red bands). Overlay (yellow bands) represents signals obtained for both α-BlaR1 and α-P-tyrosine. Sortase A (SrtA) was used as a loading control.

Densitometry analysis are the product of three independent experiments, represented as mean ± SD. Statistical analysis using an unpaired Student's t-test. ns = not significant with $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Fig 6




Figure 6:

a) Nafcillin and GWX co-treatment increases the survival of MRSA-infected *C. elegans*. Survival assay of *C. elegans* infected with Wt and Δ*stk1* with or without treatment, at 72 hours. Treatment was carried out either with 2 µg/mL nafcillin, 2.5 µg/mL GWX, or co-treated with both nafcillin and GWX.

b) Summary of findings. In USA300 and contemporary clinical strains, where broad-spectrum β-lactam resistance is attributed to the BlaR1-BlaI pathway, inhibition of Stk1 function results in β-lactam susceptibility, making Stk1 a promising therapeutic target. The loss of Stk1 (right panel) hampers the phosphorylation of BlaR1, precluding it from being efficiently incorporated into the cell membrane. On β-lactam exposure, the ability of BlaR1 to successfully mediate signal transduction to cause cleavage of the BlaI repressor was impaired, resulting in attenuated de-repression of *mecA*, which in turn decreases expression of PBP2a, culminating in β-lactam susceptibility.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarytext.pdf
- Supplementaryfigures.pdf